Yelak Biru: How pharma medical affairs and innovation teams can learn from Myelo’s AI journey
Yelak Biru, President and Chief Executive Officer at International Myeloma Foundation, shared a post on X:
“Beyond Information: How Pharma Medical Affairs and Innovation Teams Can Learn from Myelo’s AI Journey.
A few days ago, I shared Myelo’s story – an AI chatbot supporting myeloma patients.
Today, let’s explore what pharma can learn from it.
Myelo was built within a nonprofit (IMF), but its core principles apply to pharma: medical strategy, patient engagement and AI adoption.
Here’s what Pharma Medical Affairs and Innovation Teams can take away from Myelo’s impact.
Deep Stakeholder Understanding is Key
Myelo was built on deep insights into patient and HCP needs. Pharma Medical Affairs should do the same – understanding HCPs, patients, caregivers and payers to uncover unmet needs and information gaps.
Identify and Fill Information Voids
Myelo addressed gaps in patient education. Pharma Medical Affairs can use AI to improve engagement on product launches, treatment pathways, real-world evidence and medical education.
Use AI to Enhance Medical Information Delivery
Myelo is an ‘always-on’ resource, augmenting human support teams. Pharma can leverage AI chatbots for rapid, accurate responses to HCP and patient inquiries – freeing experts for complex engagements.
Personalized Engagement with AI
Myelo provided tailored learning paths for patients. Pharma can use AI to personalize medical education, scientific updates and patient support, ensuring the right info reaches the right audience.
Empower HCP-Patient Decision-Making
Myelo helps patients have better-informed discussions with their doctors. Pharma Medical Affairs can apply AI to provide evidence-based insights that support shared decision-making.
AI for Patient Support and Adherence
Myelo identified patient barriers and provided interventions. Pharma can explore AI-driven programs to enhance patient support and improve medication adherence.
Iterate and Scale AI Solutions
Myelo evolved from patient support to MyeloMD, a provider-facing tool. Pharma should start with focused AI applications, iterate based on learnings and scale successful initiatives.
The Myelo story proves how AI, strategy and deep stakeholder understanding can transform healthcare.”
More posts featuring Yelak Biru.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023